Otros idiomas Kobayashi Pharmaceutical Co., Ltd.

Acciones

4967

JP3301100008

Productos personales

Diferido Japan Exchange Otros sitios de cotización 02:25:37 13/03/2026			Variación 5 días	Varia. 1 de enero.
5.633,00 ^JPY	+1,44 %		+0,50 %	+3,94 %

10/03	Alerta de controversia de Glass Lewis: Kobayashi Pharmaceutical	MT
06/03	Oasis Management Company insta a los accionistas a oponerse a la transición de Kobayashi Pharma	CI

Otros idiomas

10/03	Glass Lewis Controversy Alert: Kobayashi Pharmaceutical
06/03	Oasis Management Company Urges Shareholders to Oppose Kobayashi Pharma?s Transition
06/03	Oasis Urges Shareholders to Oppose Kobayashi Pharma’s Transition to a Company with an Audit and Supervisory Committee at AGM (Securities Code: 4967 JT)
03/03	Kobayashi Pharmaceutical Announces Partial Withdrawal of Shareholder Proposal Ahead of 108th Annual General Meeting
10/02	Kobayashi Pharmaceutical Opposes Shareholder Proposals from Oasis Japan Strategic Fund
10/02	Kobayashi Pharmaceutical Opposes Shareholder Proposals from Oasis Japan Strategic Fund
21/01	Oasis Submits Shareholder Proposals to Kobayashi Pharmaceutical
21/01	Oasis urges Kobayashi Pharma shareholders to vote against re-nomination of Akihiro Kobayashi and Yoshiro Katae
21/01	Oasis Submits Shareholder Proposals to Kobayashi Pharmaceutical for 2026 AGM
26/12	Oasis Management raises stake in Kobayashi Pharmaceutical to 13.06% from 10.10%, filing shows
11/11	Kobayashi Pharmaceutical : Financial Overview for Third Quarter of Fiscal 2025(Fiscal Year Ending December 31, 2025)
14/10/25	Court Proceedings Begin in Oasiss Shareholder Derivative Lawsuit Seeking Director Accountability for Kobayashi Pharmaceutical Beni Koji Supplement Tragedy
14/10/25	Court Proceedings Begin in Oasis’s Shareholder Derivative Lawsuit Seeking Director Accountability for Kobayashi Pharmaceutical Beni-Koji Supplement Tragedy
12/06/25	Kobayashi Pharmaceutical Co., Ltd. Require Kazumasa Kobayashi and Akihiro Kobayashi to Resign from Their Roles as Special Advisor and Director in Charge of Compensation, Respectively
12/06/25	Voting Cards Reveal that Over 50% of Shareholders Excluding the Founding Family and Related Parties Voted For Oasis’s EGM Proposals and Against Mr. Akihiro Kobayashi’s Renomination at the AGM
09/05/25	Kobayashi Pharmaceutical : FY2025（January 1, 2025 - December 31, 2025）1Q Financial Statement
09/05/25	Kobayashi Pharmaceutical : Financial Overview for First Quarter of Fiscal 2025(Fiscal Year Ending December 31, 2025)
25/04/25	Kobayashi Pharmaceutical Co Ltd - Received Notice Of Lawsuit Filing From Shareholder Oasis Japan Strategic Fund
25/04/25	Kobayashi Pharmaceutical Co Receives a Notice Regarding Shareholder Derivative Lawsuit
07/04/25	Oasis Management - Filed Shareholder Derivative Lawsuit Against Kobayashi Pharmaceutical Directors
07/04/25	Oasis Files Shareholder Derivative Lawsuit Against Kobayashi Pharmaceutical Directors
06/04/25	Oasis Files Shareholder Derivative Lawsuit Against Kobayashi Pharmaceutical Directors
28/03/25	Kobayashi Pharmaceutical Co. Announces CEO Changes
28/03/25	Kobayashi Pharmaceutical Co. Announces Executive Changes
28/03/25	Declaration of Voting Results by Kobayashi Pharmaceutical